Medicover AB (publ)

OM:MCOV B Stock Report

Market Cap: SEK 27.4b

Medicover Valuation

Is MCOV B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MCOV B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MCOV B (SEK182.4) is trading above our estimate of fair value (SEK44.02)

Significantly Below Fair Value: MCOV B is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MCOV B?

Other financial metrics that can be useful for relative valuation.

MCOV B key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.8x
Enterprise Value/EBITDA19.3x
PEG Ratio2.5x

Price to Earnings Ratio vs Peers

How does MCOV B's PE Ratio compare to its peers?

The above table shows the PE ratio for MCOV B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average36.5x
DEDI Dedicare
7.2x8.9%SEK 640.7m
EKTA B Elekta
18.4x14.4%SEK 23.9b
ATT Attendo
17.9x23.5%SEK 7.1b
SECT B Sectra
102.5x19.3%SEK 43.9b
MCOV B Medicover
102.4x41.4%SEK 27.4b

Price-To-Earnings vs Peers: MCOV B is expensive based on its Price-To-Earnings Ratio (102.4x) compared to the peer average (36.5x).

Price to Earnings Ratio vs Industry

How does MCOV B's PE Ratio compare vs other companies in the European Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a34.8%
 n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a34.8%
 n/an/an/a
No more companies

Price-To-Earnings vs Industry: MCOV B is expensive based on its Price-To-Earnings Ratio (102.4x) compared to the European Healthcare industry average (19.1x).

Price to Earnings Ratio vs Fair Ratio

What is MCOV B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MCOV B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio102.4x
Fair PE Ratio43.8x

Price-To-Earnings vs Fair Ratio: MCOV B is expensive based on its Price-To-Earnings Ratio (102.4x) compared to the estimated Fair Price-To-Earnings Ratio (43.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MCOV B forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 182.40
SEK 207.63
+13.8%
9.3%SEK 222.20SEK 180.31n/a3
Jul ’25SEK 192.60
SEK 195.12
+1.3%
8.2%SEK 211.95SEK 173.48n/a3
Jun ’25SEK 196.80
SEK 199.13
+1.2%
8.2%SEK 220.14SEK 180.18n/a3
May ’25SEK 175.00
SEK 199.13
+13.8%
8.2%SEK 220.14SEK 180.18n/a3
Apr ’25SEK 138.00
SEK 190.26
+37.9%
5.4%SEK 203.56SEK 178.75n/a3
Mar ’25SEK 142.50
SEK 190.26
+33.5%
5.4%SEK 203.56SEK 178.75n/a3
Feb ’25SEK 170.60
SEK 201.25
+18.0%
9.0%SEK 220.52SEK 171.59n/a4
Jan ’25SEK 150.10
SEK 201.25
+34.1%
9.0%SEK 220.52SEK 171.59n/a4
Dec ’24SEK 143.20
SEK 213.90
+49.4%
10.6%SEK 236.19SEK 177.15n/a4
Nov ’24SEK 126.80
SEK 223.16
+76.0%
11.0%SEK 248.27SEK 183.14n/a4
Oct ’24SEK 143.70
SEK 223.16
+55.3%
11.0%SEK 248.27SEK 183.14n/a4
Sep ’24SEK 155.40
SEK 223.16
+43.6%
11.0%SEK 248.27SEK 183.14n/a4
Aug ’24SEK 157.50
SEK 219.66
+39.5%
10.5%SEK 240.64SEK 180.48SEK 187.404
Jul ’24SEK 163.70
SEK 224.27
+37.0%
12.0%SEK 251.43SEK 179.69SEK 192.604
Jun ’24SEK 167.70
SEK 219.29
+30.8%
10.8%SEK 244.17SEK 180.49SEK 196.804
May ’24SEK 169.10
SEK 214.01
+26.6%
9.7%SEK 232.10SEK 179.95SEK 175.004
Apr ’24SEK 168.00
SEK 205.00
+22.0%
15.5%SEK 227.89SEK 150.37SEK 138.004
Mar ’24SEK 178.80
SEK 200.94
+12.4%
15.1%SEK 225.58SEK 148.85SEK 142.504
Feb ’24SEK 179.30
SEK 178.04
-0.7%
19.4%SEK 236.97SEK 150.04SEK 170.604
Jan ’24SEK 139.70
SEK 178.04
+27.4%
19.4%SEK 236.97SEK 150.04SEK 150.104
Dec ’23SEK 142.20
SEK 178.04
+25.2%
19.4%SEK 236.97SEK 150.04SEK 143.204
Nov ’23SEK 134.70
SEK 199.05
+47.8%
17.4%SEK 241.32SEK 153.09SEK 126.804
Oct ’23SEK 119.70
SEK 193.35
+61.5%
15.3%SEK 229.64SEK 152.40SEK 143.704
Sep ’23SEK 131.30
SEK 193.35
+47.3%
15.3%SEK 229.64SEK 152.40SEK 155.404
Aug ’23SEK 152.20
SEK 191.70
+26.0%
15.2%SEK 227.39SEK 150.91SEK 157.504

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.